Trial reportStroke2020
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Trial report in Stroke, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07553650 (Master Study Protocol for the Cohort of the Specialist Network Stroke), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke) (Stroke-CORE)
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Risk Stratification Tools to Guide a Personalized Approach for Cardiac Monitoring in Embolic Stroke of Undetermined Source.Journal of the American Heart Association · 2023Pooled it
- Predicting risk of AF in ischaemic stroke using sinus rhythm ECG abnormalities: A meta-analysis.European stroke journal · 2023Pooled it
- Brazilian Atrial Fibrillation Guidelines - 2025.Arquivos brasileiros de cardiologia · 2025Article
- On Neurocardiology Updates: an Interdisciplinary Field at the Intersection of Neurology and Cardiology.Current neurology and neuroscience reports · 2025Review
- Shifting Outcomes: Superior Functional Recovery in Embolic Stroke of Undetermined Source Compared to Cardioembolic Stroke.Neurology international · 2025Article
- Academic and Community Hospitals differ in stroke subtype classification and cardiac monitoring: the DiVERT multi-center cohort study.Frontiers in neurology · 2024Article
- Independent external validation of a stroke recurrence score in patients with embolic stroke of undetermined source.Neurological research and practice · 2023Article
- Editorial: Anticoagulation in cardiovascular diseases: evolving role, unmet needs, and grey areas.Frontiers in cardiovascular medicine · 2023Article
- Embolic stroke of undetermined source: identification of patient subgroups for oral anticoagulation treatment.Neural regeneration research · 2022Article
- Forge AHEAD with stricter criteria in future trials of embolic stroke of undetermined source.Neural regeneration research · 2022Article
- A Linarin Derivative Protects against Ischemia-Induced Neuronal Injury in Mice by Promoting Cerebral Blood Flow Recovery via KDELR-Dependent CSPG4 Activation.Oxidative medicine and cellular longevity · 2022Article
- The Relationship Between Aortic Arch Calcification and Recurrent Stroke in Patients With Embolic Stroke of Undetermined Source-A Case-Control Study.Frontiers in neurology · 2022Article
- Cryptogenic Stroke and Embolic Stroke of Undetermined Source: Risk Factors and Approaches for Detection of Atrial Fibrillation.Current cardiology reviews · 2022Review
- Prevalence and predictors of atrial fibrillation in patients with embolic stroke of undetermined source: a real-life single-center retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Absent Left Anterior Descending Coronary Artery as a Potential Cause of Ischemic Stroke: A Case Report.The American journal of case reports · 2021Article
- Therapeutic management in a pregnant patient with acute ischemic stroke in the revascularization window: A case report.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 20 institutions in 9 countries.
Funding
Abstract
Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods- RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to <50 mL/minute) twice daily compared with aspirin 100 mg once daily. The primary outcome was recurrent stroke. Results- The trial, which enrolled 5390 patients from December 2014 to January 2018, did not demonstrate superiority of dabigatran versus aspirin for prevention of recurrent stroke in patients with embolic stroke of undetermined source. However, among the population qualifying for the lower dabigatran dose, the rate of recurrent stroke was reduced with dabigatran versus aspirin (7.4% versus 13.0%; hazard ratio, 0.57 [95% CI, 0.39-0.82]; interaction
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.